BRAF and metastatic melanoma: In the BRIM3 trial, vemurafenib has shown remarkable activity against BRAF V600E metastatic melanoma, with 80% of patients showing either partial or complete remission, 74% reduction in disease progression or death, and a survival advantage over patients treated with dacarbazine alone, the standard of care (Chapman et al., 2011).